N-(6-quinolyl)glycine hydrazide | 121810-78-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(6-quinolyl)glycine hydrazide
• 英文别名: 2-(6-Quinolylamino)acetohydrazide；2-(quinolin-6-ylamino)acetohydrazide
• CAS: 121810-78-4
• 化学式: C₁₁H₁₂N₄O
• 分子量: 216.242
• InChiKey: KPSSQAWXCGTTJC-UHFFFAOYSA-N

物化性质

• 熔点：
  168-169 °C
• 沸点：
  549.8±30.0 °C(Predicted)
• 密度：
  1.331±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  80
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-氨基喹啉 在 盐酸 、 sodium cyanoborohydride 、 一水合肼 作用下， 以 乙醇 、 水 、 乙腈 为溶剂， 反应 63.0h， 生成 N-(6-quinolyl)glycine hydrazide
  参考文献：
  名称：

  Synthesis and antitubercular activity of N-(2-naphthyl)glycine hydrazide analogs

  摘要：

  N-(2-Naphthyl)glycine hydrazide analogues were synthesized and tested for possible in vitro antitubercular activity. N-(2-Naphthyl)alanine hydrazide (3), N-methyl-N-(2-naphthyl)glycine hydrazide (5), N-(6-methoxy-2-naphthyl)glycine hydrazide (7), and 3-(2-naphthylamino)butyric acid hydrazide (23) showed potent inhibitory action against Mycobacterium tuberculosis H37Rv in Youman's medium at concentrations ranging from 0.5 to 10.0 micrograms/mL. These compounds showed significant inhibitory action against isonicotinic acid hydrazide and streptomycin-resistant strains of M. tuberculosis. N-(6-Quinolyl)glycine hydrazide (18) and 3-(2-quinolylamino)butyric acid hydrazide (24), which are bioisosteres of compounds 1 and 23, showed loss of antitubercular activity at low concentrations.

  DOI：

  10.1021/jm00131a002

文献信息

• Hydrazide-containing CFTR inhibitor compounds and uses thereof
  申请人：Verkman Alan

  公开号：US20050239740A1

  公开（公告）日：2005-10-27

  The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR.

  该发明提供了用于抑制囊性纤维化跨膜传导调节蛋白（CFTR）的组合物、药物制剂和方法，这些组合物、药物制剂和方法对于研究和治疗CFTR介导的疾病和病况非常有用。该发明的组合物和药物制剂可能包括一个或多个含有肼基的化合物，并且可能另外包括一个或多个药用载体、赋形剂和/或辅助剂。该发明的方法包括，在某些实施例中，向患有CFTR介导的疾病或病况的患者施用一定量的含有肼基的化合物。在其他实施例中，该发明提供了一种抑制CFTR的方法，其中包括将患者体内的细胞与一定量的含有肼基的化合物接触。此外，该发明还提供了一种CFTR介导的疾病的非人类动物模型，该模型是通过向非人类动物施用足以抑制CFTR的肼基化合物而产生的。
• HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF
  申请人：Verkman Alan

  公开号：US20090048207A1

  公开（公告）日：2009-02-19

  The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR.

  本发明提供了抑制囊性纤维化跨膜传导调节蛋白（CFTR）的组合物、制药制剂和方法，这些组合物、制药制剂和方法对于研究和治疗CFTR介导的疾病和病状非常有用。本发明的组合物和制药制剂可以包括一个或多个含有肼基的化合物，并且可能还包括一个或多个药学上可接受的载体、赋形剂和/或佐剂。本发明的方法包括，在某些实施例中，向患有CFTR介导的疾病或病状的患者施用有效量的含有肼基的化合物。在其他实施例中，本发明提供了抑制CFTR的方法，包括将含有肼基的化合物的有效量与受体中的细胞接触。此外，本发明还提供了一种CFTR介导的动物疾病的非人类动物模型，该模型通过向非人类动物施用足以抑制CFTR的含有肼基的化合物而产生。
• RAMAMURTHY, B.;BHATT, M. V., J. MED. CHEM., 32,(1989) N1, C. 2421-2426
  作者：RAMAMURTHY, B.、BHATT, M. V.

  DOI：——

  日期：——
• EP1740532A4
  申请人：——

  公开号：EP1740532A4

  公开（公告）日：2009-06-10
• US7414037B2
  申请人：——

  公开号：US7414037B2

  公开（公告）日：2008-08-19